• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>other >Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules
【2h】

Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules

机译：分析多因素介导的致病模块参芪复方和罗格列酮治疗糖尿病血管病变的疗效比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atherosclerosis-predominant vasculopathy is a common complication of diabetes with high morbidity and high mortality, which is ruining the patient's daily life. As is known to all, traditional Chinese medicine (TCM) SHENQI compound and western medicine rosiglitazone play an important role in the treatment of diabetes. In particular, SHENQI compound has a significant inhibitory effect on vascular lesions. Here, to explore and compare the therapeutic mechanism of SHENQI compound and rosiglitazone on diabetic vasculopathy, we first built 7 groups of mouse models. The behavioral, physiological and pathological morphological characteristics of these mice showed that SHENQI compound has a more comprehensive curative effect than rosiglitazone and has a stronger inhibitory effect on vascular lesions. While rosiglitazone has a more effective but no significant effect on hypoglycemic. Further, based on the gene expression of mice in each group, we performed differential expression analysis. The functional enrichment analysis of these differentially expressed genes (DEGs) revealed the potential pathogenesis and treatment mechanisms of diabetic angiopathy. In addition, we found that SHENQI compound mainly exerts comprehensive effects by regulating MCM8, IRF7, CDK7, NEDD4L by pivot regulator analysis, while rosiglitazone can rapidly lower blood glucose levels by targeting PSMD3, UBA52. Except that, we also identified some pivot TFs and ncRNAs for these potential disease-causing DEG modules, which may the mediators bridging drugs and modules. Finally, similar to pivot regulator analysis, we also identified the regulation of some drugs (e.g. bumetanide, disopyramide and glyburide etc.) which have been shown to have a certain effect on diabetes or diabetic angiopathy, proofing the scientific and objectivity of this study. Overall, this study not only provides an in-depth comparison of the efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy, but also provides clinicians and drug designers with valuable theoretical guidance.
机译：动脉粥样硬化为主的血管病是糖尿病的常见并发症，具有高发病率和高死亡率，这正在破坏患者的日常生活。众所周知，中药肾气复方和西药罗格列酮在糖尿病治疗中起着重要作用。特别地，参芪化合物对血管病变具有显着的抑制作用。在这里，为了探索和比较参芪复方和罗格列酮对糖尿病性血管病的治疗机制，我们首先建立了7组小鼠模型。这些小鼠的行为，生理和病理形态特征表明，参芪复方具有比罗格列酮更全面的治疗作用，对血管病变的抑制作用更强。罗格列酮对降血糖作用更有效，但无明显作用。此外，基于每组小鼠的基因表达，我们进行了差异表达分析。这些差异表达基因（DEGs）的功能富集分析揭示了糖尿病性血管病的潜在发病机理和治疗机制。此外，我们发现，SHENQI化合物主要通过枢轴调节器分析通过调节MCM8，IRF7，CDK7，NEDD4L发挥综合作用，而罗格列酮可通过靶向PSMD3，UBA52迅速降低血糖水平。除此之外，我们还为这些潜在的致病性DEG模块鉴定了一些关键的TF和ncRNA，这些介质可能是药物和模块之间的桥梁。最后，类似于枢轴调节剂分析，我们还确定了对某些药物（例如布美他尼，二吡酰胺和格列本脲等）的调节，这些药物对糖尿病或糖尿病性血管病具有一定作用，证明了这项研究的科学性和客观性。总的来说，这项研究不仅提供了深芪复方和罗格列酮在糖尿病性血管病治疗中的深入比较，而且为临床医生和药物设计者提供了有价值的理论指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号